Literature DB >> 21561782

SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells.

Muriel Bonnet1, Jack U Flanagan, Denise A Chan, Edwin W Lai, Phuong Nguyen, Amato J Giaccia, Michael P Hay.   

Abstract

We recently identified a class of pyridyl aniline thiazoles (PAT) that displayed selective cytotoxicity for von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC) cells in vitro and in vivo. Structure-activity relationship (SAR) studies were used to develop a comparative molecular field analysis (CoMFA) model that related VHL-selective potency to the three-dimensional arrangement of chemical features of the chemotype. We now report the further molecular alignment-guided exploration of the chemotype to discover potent and selective PAT analogues. The contribution of the central thiazole ring was explored using a series of five- and six-membered ring heterocyclic replacements to vary the electronic and steric interactions in the central unit. We also explored a positive steric CoMFA contour adjacent to the pyridyl ring using Pd-catalysed cross-coupling Suzuki-Miyaura, Sonogashira and nucleophilic displacement reactions to prepare of a series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively. In vitro potency and selectivity were determined using paired RCC cell lines: the VHL-null cell line RCC4 and the VHL-positive cell line RCC4-VHL. Active analogues selectively induced autophagy in RCC4 cells. We have used the new SAR data to further develop the CoMFA model, and compared this to a 2D-QSAR method. Our progress towards realising the therapeutic potential of this chemotype as a targeted cytotoxic therapy for the treatment of RCC by exploiting the absence of the VHL tumour suppressor gene is reported.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561782      PMCID: PMC3115526          DOI: 10.1016/j.bmc.2011.04.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  22 in total

Review 1.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.

Authors:  B Knebelmann; S Ananth; H T Cohen; V P Sukhatme
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

Review 4.  Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics.

Authors:  Denise A Chan; Amato J Giaccia
Journal:  Cell Cycle       Date:  2008-10-12       Impact factor: 4.534

5.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

Authors:  O Iliopoulos; A P Levy; C Jiang; W G Kaelin; M A Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

Review 6.  Renal cell carcinoma: etiology, incidence and epidemiology.

Authors:  Masaru Murai; Mototsugu Oya
Journal:  Curr Opin Urol       Date:  2004-07       Impact factor: 2.309

7.  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.

Authors:  Francis X Tavares; Joyce A Boucheron; Scott H Dickerson; Robert J Griffin; Frank Preugschat; Stephen A Thomson; Tony Y Wang; Hui-Qiang Zhou
Journal:  J Med Chem       Date:  2004-09-09       Impact factor: 7.446

8.  Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Authors:  Peter Staller; Jitka Sulitkova; Joanna Lisztwan; Holger Moch; Edward J Oakeley; Wilhelm Krek
Journal:  Nature       Date:  2003-09-18       Impact factor: 49.962

9.  A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Authors:  Sandra Turcotte; Denise A Chan; Patrick D Sutphin; Michael P Hay; William A Denny; Amato J Giaccia
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

10.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

Authors:  M Ohh; R L Yauch; K M Lonergan; J M Whaley; A O Stemmer-Rachamimov; D N Louis; B J Gavin; N Kley; W G Kaelin; O Iliopoulos
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

View more
  3 in total

1.  Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.

Authors:  Muriel Bonnet; Jack U Flanagan; Denise A Chan; Amato J Giaccia; Michael P Hay
Journal:  Bioorg Med Chem       Date:  2013-12-20       Impact factor: 3.641

2.  Site-selective Suzuki-Miyaura coupling of heteroaryl halides - understanding the trends for pharmaceutically important classes.

Authors:  Joshua Almond-Thynne; David C Blakemore; David C Pryde; Alan C Spivey
Journal:  Chem Sci       Date:  2016-08-09       Impact factor: 9.825

3.  CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds.

Authors:  Alexey A Lagunin; Varvara I Dubovskaja; Anastasia V Rudik; Pavel V Pogodin; Dmitry S Druzhilovskiy; Tatyana A Gloriozova; Dmitry A Filimonov; Narahari G Sastry; Vladimir V Poroikov
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.